Over 95% of our patients provide regular data points that allow us to adjust medication plans in real time and drive continuous improvement, said Dr
Researchers with existing cardiovascular disease, elevated baseline TMAO levels, or significant cardiovascular risk factors should discuss this specific concern with their healthcare provider before starting a levocarnitine-containing compound
High medical and pharmaceutical costs are likely to continue, as are premium hikes
Since the FDAs approval of Wegovy in 2021, GLP-1 drugs have seen explosive demand that has resulted in shortages of supply over the past year
Many people notice they have more energy for physical activity as they lose weight, creating a positive cycle where increased movement further supports cardiovascular health
Kroneis, T., Jonasson, E., Andersson, D., Dolatabadi, S